Researchers have validated in the lab a computer model that predicts key information about nasal insulin treatment regimens for Type 1 diabetes. The work, which confirms that modeling can optimize the efficacy of nasal insulin immunotherapy, also supports the use of humanized platforms in the design of clinical trials.
The Type 1 Diabetes PhysioLab Platform models disease pathogenesis based on non-obese diabetic mice. The findings, by a La Jolla Institute team led by Matthias von Herrath, show the platform can predict critical Type 1 diabetes biomarkers. It streamlines experimental design by pinpointing when biomarkers associated with protection in mice are induced.
The platform was developed over two years with input from independent experts. It simulates autoimmune processes and the subsequent destruction of insulin-producing pancreatic beta cells, the underlying cause of Type 1 diabetes, from birth through onset of the disease.
"Virtual Optimization of Nasal Insulin Therapy Predicts Immunization Frequency to be Crucial for Diabetes Protection" appears in the December issue of Diabetes.